Regulatory Overhaul Needed For Innovative Techs, Gottlieb Says

In a speech last week, former US FDA Commissioner Scott Gottlieb said establishing dynamic tools, including active registries and firm-based regulation, will be crucial to the FDA’s ability to regulate emerging technologies. 

FDA Commissioner, Scott Gottlieb, holds FDA All-Hands

A failed Congressional attempt to overhaul the regulation of lab-developed tests might hold the seeds of a better approach to the regulation of innovative technology, former US Food and Drug Administration Commissioner Scott Gottlieb said at the Food & Drug Law Institute (FDLI) annual conference in Washington, DC, on 17 May.

Gottlieb, who is now a senior fellow at the American Enterprise Institute, served as the FDA’s commissioner between 2017 and...

More from Regulation

More from Policy & Regulation